Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2016

Open Access 01-12-2016 | Research article

Systematic review of non-surgical treatments for early Dupuytren’s disease

Authors: Catherine Ball, David Izadi, Liaquat Suleman Verjee, James Chan, Jagdeep Nanchahal

Published in: BMC Musculoskeletal Disorders | Issue 1/2016

Login to get access

Abstract

Background

Dupuytren’s disease is a common fibrotic disorder of the palm characterized by the development of progressive flexion deformities in the digits, leading to significant functional impairment. Surgical excision remains the most common treatment. However, this is only indicated in patients with established contractures rather than those with early disease. Early disease is generally characterized by the presence of palmar nodules with limited or no contracture of the fingers. The ideal treatment would be directed at patients with early progressive disease to prevent future deterioration. Various non-surgical treatment modalities have been described but there is currently no systematic assessment of the role and efficacy of these treatments in patients with early disease.

Methods

Using a PICOS analysis we reviewed publications of studies of patients with early disease who had received physical therapies, pharmacological treatment, or radiotherapy. Following PRISMA guidelines titles and abstract were screened using predefined criteria to identify those reporting outcomes specifically relating to the treatment of early disease. In the absence of a definition of early disease studies were included if early DD was described clinically, with digital contractures not exceeding 30°, Tubiana grades N to 1, and which reported identifiable data. Studies were excluded if data for early DD patients could not be extracted for analysis.

Results

In this systematic review, 26 studies were identified and analyzed to evaluate the effect of pharmacological therapy (n = 11), physical therapy (n = 5) and radiotherapy (n = 10) on early Dupuytren’s disease. The studies comprised 20 case series, 1 cohort study with the remainder reporting case studies. All publications were graded level of evidence 4 or 5 assessed using the Oxford Centre for Evidence Based Medicine grading. Narrative descriptions of the data are presented.

Conclusions

Physical therapies were the most robustly assessed, using objective measures but the studies were under powered, providing insufficient evidence of efficacy. Intralesional steroid injection and radiotherapy appeared to lead to softening of nodules and to retard disease progression but lacked rigorous evaluation and studies were poorly designed. There is an urgent need for adequately powered double blinded randomized trials for this common disorder which affects 4 % of the population.

Trial registration

The protocol was registered (CRD42015008986 16 November 2015) with the PROSPERO international prospective register of systematic reviews.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren’s disease incidence and prevalence rates in relation to etiology. Hand (N Y). 2009;4:256–69.CrossRef Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren’s disease incidence and prevalence rates in relation to etiology. Hand (N Y). 2009;4:256–69.CrossRef
2.
go back to reference Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand (N Y). 2011;6:149–58.CrossRef Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand (N Y). 2011;6:149–58.CrossRef
3.
go back to reference Lanting R, Broekstra DC, Werker PM, van den Heuvel ER. A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries. Plast Reconstr Surg. 2014;133:593–603.CrossRefPubMed Lanting R, Broekstra DC, Werker PM, van den Heuvel ER. A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries. Plast Reconstr Surg. 2014;133:593–603.CrossRefPubMed
4.
go back to reference Rombouts JJ, Noel H, Legrain Y, Munting E. Prediction of recurrence in the treatment of Dupuytren’s disease: evaluation of a histologic classification. J Hand Surg [Am]. 1989;14:644–52.CrossRef Rombouts JJ, Noel H, Legrain Y, Munting E. Prediction of recurrence in the treatment of Dupuytren’s disease: evaluation of a histologic classification. J Hand Surg [Am]. 1989;14:644–52.CrossRef
5.
go back to reference Gudmundsson KG, Arngrimsson R, Jonsson T. Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren’s disease. Scand J Rheumatol. 2001;30:31–4.CrossRefPubMed Gudmundsson KG, Arngrimsson R, Jonsson T. Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren’s disease. Scand J Rheumatol. 2001;30:31–4.CrossRefPubMed
6.
go back to reference Reilly RM, Stern PJ, Goldfarb CA. A retrospective review of the management of Dupuytren’s nodules. J Hand Surg [Am]. 2005;30:1014–8.CrossRef Reilly RM, Stern PJ, Goldfarb CA. A retrospective review of the management of Dupuytren’s nodules. J Hand Surg [Am]. 2005;30:1014–8.CrossRef
7.
go back to reference Lanting R, Van den Heuvel ER, Werker PM. Clusters in Short-term Disease Course in Participants With Primary Dupuytren Disease. J Hand Surg [Am]. 2016;41:354–61.CrossRef Lanting R, Van den Heuvel ER, Werker PM. Clusters in Short-term Disease Course in Participants With Primary Dupuytren Disease. J Hand Surg [Am]. 2016;41:354–61.CrossRef
8.
go back to reference Luck JV. Dupuytren’s contracture; a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg Am. 1959;41-A:635–64.CrossRefPubMed Luck JV. Dupuytren’s contracture; a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg Am. 1959;41-A:635–64.CrossRefPubMed
9.
go back to reference Lam WL, Rawlins JM, Karoo RO, Naylor I, Sharpe DT. Re-visiting Luck’s classification: a histological analysis of Dupuytren’s disease. J Hand Surg Eur Vol. 2010;35:312–7.CrossRefPubMed Lam WL, Rawlins JM, Karoo RO, Naylor I, Sharpe DT. Re-visiting Luck’s classification: a histological analysis of Dupuytren’s disease. J Hand Surg Eur Vol. 2010;35:312–7.CrossRefPubMed
10.
go back to reference Chiu HF, McFarlane RM. Pathogenesis of Dupuytren’s contracture: a correlative clinical-pathological study. J Hand Surg [Am]. 1978;3:1–10.CrossRef Chiu HF, McFarlane RM. Pathogenesis of Dupuytren’s contracture: a correlative clinical-pathological study. J Hand Surg [Am]. 1978;3:1–10.CrossRef
11.
go back to reference Verjee LS, Verhoekx JS, Chan JK, Krausgruber T, Nicolaidou V, Izadi D, Davidson D, Feldmann M, Midwood KS, Nanchahal J. Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target. Proc Natl Acad Sci U S A. 2013;110:E928–37.CrossRefPubMedPubMedCentral Verjee LS, Verhoekx JS, Chan JK, Krausgruber T, Nicolaidou V, Izadi D, Davidson D, Feldmann M, Midwood KS, Nanchahal J. Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target. Proc Natl Acad Sci U S A. 2013;110:E928–37.CrossRefPubMedPubMedCentral
12.
go back to reference Early PF. Population studies in Dupuytren's contracture. J Bone Joint Surg (Br). 1962;44-B:602–13. Early PF. Population studies in Dupuytren's contracture. J Bone Joint Surg (Br). 1962;44-B:602–13.
13.
go back to reference Iselin M, Dieckmann G. Our experiences in the treatment of Dupuytren’s disease. Mem Acad Chir. 1951;77:251–5.PubMed Iselin M, Dieckmann G. Our experiences in the treatment of Dupuytren’s disease. Mem Acad Chir. 1951;77:251–5.PubMed
14.
go back to reference Keilholz L, Seegenschmiedt MH, Sauer R. Radiotherapy for prevention of disease progression in early-stage Dupuytren’s contracture: Initial and long-term results. Int J Radiat Oncol Biol Phys. 1996;36:891–7.CrossRefPubMed Keilholz L, Seegenschmiedt MH, Sauer R. Radiotherapy for prevention of disease progression in early-stage Dupuytren’s contracture: Initial and long-term results. Int J Radiat Oncol Biol Phys. 1996;36:891–7.CrossRefPubMed
15.
go back to reference Seegenschmiedt MH, Olschewski T, Guntrum F. Radiotherapy optimization in early-stage dupuytren’s contracture: First results of a randomized clinical study. Int J Radiat Oncol Biol Phys. 2001;49:785–98.CrossRefPubMed Seegenschmiedt MH, Olschewski T, Guntrum F. Radiotherapy optimization in early-stage dupuytren’s contracture: First results of a randomized clinical study. Int J Radiat Oncol Biol Phys. 2001;49:785–98.CrossRefPubMed
17.
go back to reference Tubiana R, Michon J, Thomine JM. Scheme for the assessment of deformities in Dupuytren’s disease. Surg Clin North Am. 1968;48:979–84.CrossRefPubMed Tubiana R, Michon J, Thomine JM. Scheme for the assessment of deformities in Dupuytren’s disease. Surg Clin North Am. 1968;48:979–84.CrossRefPubMed
18.
go back to reference Steinberg CL. Tocopherols in treatment of primary fibrositis; including Dupuytren’s contracture, periarthritis of the shoulders, and Peyronie’s disease. Arch Surg. 1951;63:824–33.CrossRef Steinberg CL. Tocopherols in treatment of primary fibrositis; including Dupuytren’s contracture, periarthritis of the shoulders, and Peyronie’s disease. Arch Surg. 1951;63:824–33.CrossRef
19.
20.
go back to reference Henry M. Dupuytren’s disease: current state of the art. Hand (N Y). 2014;9:1–8.CrossRef Henry M. Dupuytren’s disease: current state of the art. Hand (N Y). 2014;9:1–8.CrossRef
21.
go back to reference Hurst LC, Badalamente MA. Nonoperative treatment of Dupuytren’s disease. Hand Clin. 1999;15:97–107.PubMed Hurst LC, Badalamente MA. Nonoperative treatment of Dupuytren’s disease. Hand Clin. 1999;15:97–107.PubMed
22.
go back to reference Rayan GM. Nonoperative Treatment of Dupuytren’s Disease. J Hand Surg [Am]. 2008;33:1208–10.CrossRef Rayan GM. Nonoperative Treatment of Dupuytren’s Disease. J Hand Surg [Am]. 2008;33:1208–10.CrossRef
23.
go back to reference Rayan GM. Dupuytren disease: Anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am. 2007;89(1):189-198. Rayan GM. Dupuytren disease: Anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am. 2007;89(1):189-198.
24.
go back to reference Hurst L. Dupuytren’s contracture. In: Scott WW, Robert NH, William CP, Scott HK, David PG, editors. Green’s operative hand surgery Volume 1. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2011. p. 141–58.CrossRef Hurst L. Dupuytren’s contracture. In: Scott WW, Robert NH, William CP, Scott HK, David PG, editors. Green’s operative hand surgery Volume 1. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2011. p. 141–58.CrossRef
25.
go back to reference Balaguer T, David S, Ihrai T, Cardot N, Daideri G, Lebreton E. Histological staging and Dupuytren’s disease recurrence or extension after surgical treatment: a retrospective study of 124 patients. J Hand Surg Eur Vol. 2009;34:493–6.PubMed Balaguer T, David S, Ihrai T, Cardot N, Daideri G, Lebreton E. Histological staging and Dupuytren’s disease recurrence or extension after surgical treatment: a retrospective study of 124 patients. J Hand Surg Eur Vol. 2009;34:493–6.PubMed
26.
go back to reference O’Connor D, Green S, Higgins JPT. Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions version 510. Chichester: The Cochrane Collaboration; 2011. O’Connor D, Green S, Higgins JPT. Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions version 510. Chichester: The Cochrane Collaboration; 2011.
29.
go back to reference Higgins J, Altman D, Sterne J. Assessing risk of bias in included studies. In: Higgins JPT, Sally G, editors. Cochrane handbook for Systematic Reviews of Interventions. Chichester: The Cochrane Collaboration; 2011. p. 187–241. Higgins J, Altman D, Sterne J. Assessing risk of bias in included studies. In: Higgins JPT, Sally G, editors. Cochrane handbook for Systematic Reviews of Interventions. Chichester: The Cochrane Collaboration; 2011. p. 187–241.
30.
go back to reference Baxter H, Schiller C, Johnson LH, Whiteside JH, Randall RE. Cortisone therapy in Dupuytren’s contracture. Plast Reconstr Surg. 1952;9:261–73.CrossRef Baxter H, Schiller C, Johnson LH, Whiteside JH, Randall RE. Cortisone therapy in Dupuytren’s contracture. Plast Reconstr Surg. 1952;9:261–73.CrossRef
31.
go back to reference Ketchum LD, Donahue TK. The injection of nodules of Dupuytren’s disease with triamcinolone acetonide. J Hand Surg [Am]. 2000;25:1157–62.CrossRef Ketchum LD, Donahue TK. The injection of nodules of Dupuytren’s disease with triamcinolone acetonide. J Hand Surg [Am]. 2000;25:1157–62.CrossRef
32.
go back to reference Shelley WB, Shelley ED. Response of Dupuytren’s contracture to high-potency topical steroid [5]. Lancet. 1993;342:366.CrossRefPubMed Shelley WB, Shelley ED. Response of Dupuytren’s contracture to high-potency topical steroid [5]. Lancet. 1993;342:366.CrossRefPubMed
33.
go back to reference Zachariae L, Zachariae F. Hydrocortisone acetate in the treatment of Dupuytren’s contraction and allied conditions. Acta Chir Scand. 1955;109:421–31.PubMed Zachariae L, Zachariae F. Hydrocortisone acetate in the treatment of Dupuytren’s contraction and allied conditions. Acta Chir Scand. 1955;109:421–31.PubMed
34.
go back to reference Coste F, Weissenbach R. Treatment of Dupuytren’s disease by local injections of hydrocortisone. [Polyglot]. Rev Rhum Mal Osteoartic. 1953;20:863–6.PubMed Coste F, Weissenbach R. Treatment of Dupuytren’s disease by local injections of hydrocortisone. [Polyglot]. Rev Rhum Mal Osteoartic. 1953;20:863–6.PubMed
35.
go back to reference Reilly CP. Letter: Are vitamin E supplements beneficial? Med J Aust. 1974;2:795.PubMed Reilly CP. Letter: Are vitamin E supplements beneficial? Med J Aust. 1974;2:795.PubMed
37.
go back to reference Skliarenko ET, Gerasimenko SI. Therapy of the Dupuytren’s disease with the furazolidon. Ortop Travmatol Protez. 1982;2:45–7. Skliarenko ET, Gerasimenko SI. Therapy of the Dupuytren’s disease with the furazolidon. Ortop Travmatol Protez. 1982;2:45–7.
38.
go back to reference Gatev S, Troev T. Ultraphonophoresis with Aminosin zalbe in Dupuitren contracture. Fizikalna Kurortna i Rekhabilitatsionna Meditsina. 1997;36:31–3. Gatev S, Troev T. Ultraphonophoresis with Aminosin zalbe in Dupuitren contracture. Fizikalna Kurortna i Rekhabilitatsionna Meditsina. 1997;36:31–3.
39.
go back to reference Yildiz S, Karacaoglu E, Pehlivan O. Hyperbaric oxygen for the treatment of early-phase Dupuytren’s contracture. Microsurgery. 2004;24:26–9.CrossRefPubMed Yildiz S, Karacaoglu E, Pehlivan O. Hyperbaric oxygen for the treatment of early-phase Dupuytren’s contracture. Microsurgery. 2004;24:26–9.CrossRefPubMed
40.
go back to reference Markham DE, Wood MR. Ultrasound for Dupuytren’s contracture. Physiotherapy. 1980;66:55–8.PubMed Markham DE, Wood MR. Ultrasound for Dupuytren’s contracture. Physiotherapy. 1980;66:55–8.PubMed
41.
go back to reference Ball C, Nanchahal J. The use of splinting as a non-surgical treatment for Dupuytren’s disease: a pilot study. Br J Hand Ther. 2002;7:76–8. Ball C, Nanchahal J. The use of splinting as a non-surgical treatment for Dupuytren’s disease: a pilot study. Br J Hand Ther. 2002;7:76–8.
42.
go back to reference Larocerie-Salgado J, Davidson J. Nonoperative treatment of PIPJ flexion contractures associated with Dupuytren’s disease. J Hand Surg Eur Vol. 2012;37:722–7.CrossRefPubMed Larocerie-Salgado J, Davidson J. Nonoperative treatment of PIPJ flexion contractures associated with Dupuytren’s disease. J Hand Surg Eur Vol. 2012;37:722–7.CrossRefPubMed
43.
go back to reference Christie WS, Puhl AA, Lucaciu OC. Cross-frictional therapy and stretching for the treatment of palmar adhesions due to Dupuytren’s contracture: a prospective case study. Man Ther. 2012;17:479–82.CrossRefPubMed Christie WS, Puhl AA, Lucaciu OC. Cross-frictional therapy and stretching for the treatment of palmar adhesions due to Dupuytren’s contracture: a prospective case study. Man Ther. 2012;17:479–82.CrossRefPubMed
44.
go back to reference Onat SS, Delialioglu SU. The assessment and treatment of palmar fibromatosis with case presentations. [Turkish]. Turk Osteoporoz Dergisi. 2013;19:52–5.CrossRef Onat SS, Delialioglu SU. The assessment and treatment of palmar fibromatosis with case presentations. [Turkish]. Turk Osteoporoz Dergisi. 2013;19:52–5.CrossRef
45.
go back to reference Lukacs S, Braun-Falco O, Goldschmidt H. Radiotherapy of benign dermatoses: indications, practice, and results. J Dermatol Surg Oncol. 1978;4:620–5.CrossRefPubMed Lukacs S, Braun-Falco O, Goldschmidt H. Radiotherapy of benign dermatoses: indications, practice, and results. J Dermatol Surg Oncol. 1978;4:620–5.CrossRefPubMed
46.
go back to reference Hesselkamp J, Schulmeyer M, Wiskemann A. Radiotherapy of Dupuytren’s contracture in stage I. [German]. Therapiewoche. 1981;31:6337–8. Hesselkamp J, Schulmeyer M, Wiskemann A. Radiotherapy of Dupuytren’s contracture in stage I. [German]. Therapiewoche. 1981;31:6337–8.
47.
go back to reference Adamietz B, Keilholz L, Grunert J, Sauer R. Radiotherapy of early stage Dupuytren disease. Long-term results after a median follow-up period of 10 years. Strahlenther Onkol. 2001;177:604–10.CrossRefPubMed Adamietz B, Keilholz L, Grunert J, Sauer R. Radiotherapy of early stage Dupuytren disease. Long-term results after a median follow-up period of 10 years. Strahlenther Onkol. 2001;177:604–10.CrossRefPubMed
48.
go back to reference Kohler AH. Radiotherapy in Dupuytren’s contracture. Radiobiol Radiother. 1984;25:851–3. Kohler AH. Radiotherapy in Dupuytren’s contracture. Radiobiol Radiother. 1984;25:851–3.
49.
go back to reference Weinzierl G, Flugel M, Geldmacher J. Lack of effectiveness of alternative non-surgical treatment procedures of Dupuytren contracture. Chirurg. 1993;64:492–4.PubMed Weinzierl G, Flugel M, Geldmacher J. Lack of effectiveness of alternative non-surgical treatment procedures of Dupuytren contracture. Chirurg. 1993;64:492–4.PubMed
50.
go back to reference Corsi M. Radiotherapy of Dupuytren’s disease. Il Friuli medico. 1966;21:391–403.PubMed Corsi M. Radiotherapy of Dupuytren’s disease. Il Friuli medico. 1966;21:391–403.PubMed
51.
go back to reference Grenfell S, Borg M. Radiotherapy in fascial fibromatosis: a case series, literature review and considerations for treatment of early-stage disease. J Med Imaging Radiat Oncol. 2014;58:641–7.CrossRefPubMed Grenfell S, Borg M. Radiotherapy in fascial fibromatosis: a case series, literature review and considerations for treatment of early-stage disease. J Med Imaging Radiat Oncol. 2014;58:641–7.CrossRefPubMed
52.
go back to reference Finney R. Dupuytren’s contracture a radiotherapeutic approach. Lancet. 1953;265:1064–6.CrossRef Finney R. Dupuytren’s contracture a radiotherapeutic approach. Lancet. 1953;265:1064–6.CrossRef
54.
go back to reference Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell-mediated response in Dupuytren’s disease. Lancet. 1993;341:1622–3.CrossRefPubMed Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell-mediated response in Dupuytren’s disease. Lancet. 1993;341:1622–3.CrossRefPubMed
56.
go back to reference Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3:349–63.CrossRefPubMed Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3:349–63.CrossRefPubMed
58.
go back to reference Wick G, Grundtman C, Mayerl C, Wimpissinger TF, Feichtinger J, Zelger B, Sgonc R, Wolfram D. The immunology of fibrosis. Annu Rev Immunol. 2013;31:107–35.CrossRefPubMed Wick G, Grundtman C, Mayerl C, Wimpissinger TF, Feichtinger J, Zelger B, Sgonc R, Wolfram D. The immunology of fibrosis. Annu Rev Immunol. 2013;31:107–35.CrossRefPubMed
59.
go back to reference Creteur V, Madani A, Gosset N. Ultrasound imaging of Dupuytren’s contracture. J Radiol. 2010;91:687–91.CrossRefPubMed Creteur V, Madani A, Gosset N. Ultrasound imaging of Dupuytren’s contracture. J Radiol. 2010;91:687–91.CrossRefPubMed
61.
go back to reference Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed
63.
go back to reference Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren’s disease. J Hand Surg [Am]. 2000;25:629–36.CrossRef Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren’s disease. J Hand Surg [Am]. 2000;25:629–36.CrossRef
64.
go back to reference Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg [Am]. 2007;32:767–74.CrossRef Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg [Am]. 2007;32:767–74.CrossRef
65.
go back to reference Bainbridge C, Gerber RA, Szczypa PP, Smith T, Kushner H, Cohen B, Hellio Le Graverand-Gastineau MP. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren’s contracture. J Plast Surg Hand Surg. 2012;46:177–83.CrossRefPubMedPubMedCentral Bainbridge C, Gerber RA, Szczypa PP, Smith T, Kushner H, Cohen B, Hellio Le Graverand-Gastineau MP. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren’s contracture. J Plast Surg Hand Surg. 2012;46:177–83.CrossRefPubMedPubMedCentral
66.
go back to reference Naam NH. Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren’s contracture. Hand (N Y). 2013;8:410–6.CrossRef Naam NH. Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren’s contracture. Hand (N Y). 2013;8:410–6.CrossRef
68.
go back to reference Peimer CA, Pess G, Skodny P, Tursi J, Szczypa PP, Gerber RA. FESSH abstracts_1. J Hand Surg Eur Vol. 2012;37:S1–S84.CrossRef Peimer CA, Pess G, Skodny P, Tursi J, Szczypa PP, Gerber RA. FESSH abstracts_1. J Hand Surg Eur Vol. 2012;37:S1–S84.CrossRef
69.
go back to reference Freshwater MF. What were the adverse events for Dupuytren’s patients treated with Xiaflex who had contractures less than 20° ? Hand (N Y). 2012;7:348–9.CrossRef Freshwater MF. What were the adverse events for Dupuytren’s patients treated with Xiaflex who had contractures less than 20° ? Hand (N Y). 2012;7:348–9.CrossRef
70.
go back to reference Lanting R, van den Heuvel ER, Westerink B, Werker PM. Prevalence of Dupuytren disease in The Netherlands. Plast Reconstr Surg. 2013;132:394–403.CrossRefPubMed Lanting R, van den Heuvel ER, Westerink B, Werker PM. Prevalence of Dupuytren disease in The Netherlands. Plast Reconstr Surg. 2013;132:394–403.CrossRefPubMed
71.
go back to reference Rayan GM. Clinical presentation and types of Dupuytren’s disease. Hand Clin. 1999;15:87–96. vii.PubMed Rayan GM. Clinical presentation and types of Dupuytren’s disease. Hand Clin. 1999;15:87–96. vii.PubMed
72.
go back to reference Thurston AJ. Conservative surgery for Dupuytren’s contracture. J Hand Surg (Br). 1987;12:329–34.CrossRef Thurston AJ. Conservative surgery for Dupuytren’s contracture. J Hand Surg (Br). 1987;12:329–34.CrossRef
Metadata
Title
Systematic review of non-surgical treatments for early Dupuytren’s disease
Authors
Catherine Ball
David Izadi
Liaquat Suleman Verjee
James Chan
Jagdeep Nanchahal
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2016
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-016-1200-y

Other articles of this Issue 1/2016

BMC Musculoskeletal Disorders 1/2016 Go to the issue